{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:36:02Z","timestamp":1784784962805,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Delta University for Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The low selectivity and significant toxicity of current chemotherapeutic medicines make the research and development of novel anticancer agents an urgent necessity. This study used IR, NMR, MS, and elemental studies to rationally design, synthesize, and structurally characterize a novel class of pyrimidine-based sulfonamide derivatives. A wide variety of heterocyclic scaffolds, such as oxadiazoles, thiazolinones, chromenes, pyrazoles, pyrazolopyrimidines, triazolopyrimidines, imidazolidines, and triazines, were made possible by the synthetic approach. HepG2, MCF-7, WI-38, and VERO cell lines were used to test the synthetic compounds\u2019 cytotoxic properties. With IC\n                    <jats:sub>50<\/jats:sub>\n                    values ranging from 7.4 to 10.2\u00a0\u00b5g\/mL against HepG2 and 8.2 to 10.0\u00a0\u00b5g\/mL against MCF-7, compounds\n                    <jats:bold>18<\/jats:bold>\n                    ,\n                    <jats:bold>21<\/jats:bold>\n                    ,\n                    <jats:bold>23<\/jats:bold>\n                    , and\n                    <jats:bold>24<\/jats:bold>\n                    showed extremely significant anticancer activity, nearly matching the potency of the reference medication 5-fluorouracil. Crucially, these substances showed a good therapeutic index with noticeably reduced toxicity toward normal WI-38 and VERO cells. The most active derivatives\u2019 increased cytotoxicity and selectivity were shown to be largely due to electron-donating groups, balanced lipophilicity, and optimal heterocyclic substitution patterns, according to structure\u2013activity relationship (SAR) research. The experimental results were corroborated by molecular docking experiments against thymidylate synthase (PDB: 2VF5), where compound\n                    <jats:bold>23<\/jats:bold>\n                    exhibited the highest binding affinity (S\u2009=\u2009\u2212\u20095.5589\u00a0kcal\/mol), creating strong H-bond interactions with Lys487 and Ala498 within the active region. Overall, compounds\n                    <jats:bold>18<\/jats:bold>\n                    ,\n                    <jats:bold>21<\/jats:bold>\n                    ,\n                    <jats:bold>23<\/jats:bold>\n                    , and\n                    <jats:bold>24<\/jats:bold>\n                    are identified as interesting lead candidates for additional development as effective and selective anticancer medicines based on the combined biology, SAR, and docking results. Future optimization, mechanistic research, and even in vivo assessment can all benefit from these discoveries.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-41711-z","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:34:29Z","timestamp":1774337669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Design, synthesis, molecular docking and cytotoxic evaluation of novel pyrimidine-based sulfonamide derivatives as potent anticancer agents: SAR insights and biological profiling"],"prefix":"10.1038","volume":"16","author":[{"given":"Nesma M.","family":"Bayoumy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem E.","family":"Gaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanees N.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"41711_CR1","doi-asserted-by":"crossref","unstructured":"Elgemeie, G. H. & Mohamed-Ezzat, R. A. New Strategies Targeting Cancer Metabolism 1st edn, 1\u2013619 (Elsevier, 2022).","DOI":"10.1016\/B978-0-12-821783-2.00004-2"},{"key":"41711_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.semdp.2008.08.001","volume":"25","author":"F Rojo","year":"2008","unstructured":"Rojo, F., Albanell, J., Rovira, A., Corominas, J. M. & Manzarbeitia, F. Targeted Therapies in Breast Cancer. Semin. Diagn. Pathol. 25, 245\u2013261 (2008).","journal-title":"Semin. Diagn. Pathol."},{"key":"41711_CR3","doi-asserted-by":"publisher","first-page":"119126","DOI":"10.1016\/j.jep.2024.119126","volume":"338","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer. J. Ethnopharmacol. 338, 119126 (2025).","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"41711_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"ZB Wang","year":"2024","unstructured":"Wang, Z. B. et al. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology 173 (1), 14\u201332 (2024).","journal-title":"Immunology"},{"key":"41711_CR5","doi-asserted-by":"crossref","unstructured":"Abraham, D. Burgers Medicinal Chemistry and Drug Discovery (Hoboken, 2003).","DOI":"10.1002\/0471266949"},{"key":"41711_CR6","doi-asserted-by":"crossref","unstructured":"Anand, N., Corcoran, J. W., Hahn, F. E., Snell, J. F. & Arora, K. L. Mechanism of Action of Antimicrobial and Antitumor Agents Vol. 3, 668\u2013698 (Springer, 1975).","DOI":"10.1007\/978-3-642-46304-4_45"},{"key":"41711_CR7","unstructured":"The Nobel Prize in Physiology or Medicine. Nobel Prize.Org; Nobel Media AB, 2014. (1939)."},{"key":"41711_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0022-3565(25)23278-5","volume":"120","author":"JR Fouts","year":"1957","unstructured":"Fouts, J. R., Kamm, J. J. & Brodie, B. B. Enzymatic reduction of prontosil and other azo dyes. J. Pharmacol. Exp. Ther. 120, 291\u2013300 (1957).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"41711_CR9","unstructured":"Neo, H. C. & Gootz, T. D. Medical Microbiology 4th edn (The University of Texas Medical Branch at Galveston, 1996)."},{"key":"41711_CR10","unstructured":"VanMeter, K. C. & Hubert, R. J. Microbiology for the Healthcare Professional 2nd edn (Elsevier, 2016)."},{"key":"41711_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bmcl.2007.11.085","volume":"18","author":"ZJ Zhao","year":"2008","unstructured":"Zhao, Z. J. et al. Novel indole-3-sulfonamides as potent HIV nonnucleoside reverse transcriptase inhibitors (NNRTIs). Bioorg. Med. Chem. Lett. 18, 554\u2013559 (2008).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41711_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2174\/1389557043487402","volume":"4","author":"CT Supuran","year":"2004","unstructured":"Supuran, C. T., Innocenti, A., Mastrolorenzo, A. & Scozzafava, A. Antiviral sulfonamide derivatives. Mini-Reviews Med. Chem. 4, 189\u2013200 (2004).","journal-title":"Mini-Reviews Med. Chem."},{"key":"41711_CR13","first-page":"417","volume":"75","author":"M Garcia","year":"2009","unstructured":"Garcia, M., Diaz, S. & Barcelo, D. Combining chemical analysis and ecotoxicity to determine environmental exposure and to assess risk from sulfonamides. Trends Anal. Chem. 75, 417\u2013434 (2009).","journal-title":"Trends Anal. Chem."},{"key":"41711_CR14","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1016\/j.ejmech.2009.06.031","volume":"44","author":"S Eswaran","year":"2009","unstructured":"Eswaran, S., Adhikari, A. V. & Shetty, N. S. Synthesis and antimicrobial activities of novel quinoline derivatives carrying 1,2,4-triazole moiety. Eur. J. Med. Chem. 44, 4637\u20134647 (2009).","journal-title":"Eur. J. Med. Chem."},{"key":"41711_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/aoc.590010305","volume":"1","author":"SJ Blunden","year":"1987","unstructured":"Blunden, S. J., Patel, B. N., Smith, P. J. & Sugavanam, B. Synthesis, 119Sn NMR and M\u00f6ssbauer studies and bioassay data of O-tricyclohexylstannyl derivatives of substituted 8\u2010hydroxyquinolines. Appl. Organomet. Chem. 1, 241\u2013244 (1987).","journal-title":"Appl. Organomet. Chem."},{"key":"41711_CR16","unstructured":"Denny, W. A. et al. Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium, US Patent 7064117B2 (2006)."},{"key":"41711_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1021\/jm970044r","volume":"40","author":"LW Deady","year":"1997","unstructured":"Deady, L. W., Kaye, A. J., Finlay, G. J., Baguley, B. C. & Denny, W. A. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines. J. Med. Chem. 40, 2040\u20132046 (1997).","journal-title":"J. Med. Chem."},{"key":"41711_CR18","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.bmcl.2014.05.002","volume":"24","author":"NC Desai","year":"2014","unstructured":"Desai, N. C., Kotadiya, G. M. & Trivedi, A. R. Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs. Bioorg. Med. Chem. Lett. 24, 3126\u20133130 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41711_CR19","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1021\/jm900003c","volume":"52","author":"A Lilienkampf","year":"2009","unstructured":"Lilienkampf, A. et al. Structure\u2013activity relationships for a series of quinoline-based compounds active against Mycobacterium tuberculosis. J. Med. Chem. 52, 2109\u20132118 (2009).","journal-title":"J. Med. Chem."},{"key":"41711_CR20","first-page":"299","volume":"36","author":"A Sharma","year":"1999","unstructured":"Sharma, A. & Mishra, N. C. Inhibition of a protein tyrosine kinase activity in Plasmodium falciparum by chloroquine. Indian J. Biochem. Biophys. 36, 299\u2013304 (1999).","journal-title":"Indian J. Biochem. Biophys."},{"key":"41711_CR21","doi-asserted-by":"crossref","unstructured":"Elgemeie, G. H. et al. N-Sulfonated N-Heterocycles 1st edn, 1\u2013507 (Elsevier, 2022).","DOI":"10.1016\/B978-0-12-822179-2.00006-9"},{"key":"41711_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/13543784.12.2.283","volume":"12","author":"CT Supuran","year":"2003","unstructured":"Supuran, C. T. Indisulam: An anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs. 12, 283\u2013287 (2003).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"41711_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/13543776.2018.1487400","volume":"28","author":"\u0130 Gul\u00e7in","year":"2018","unstructured":"Gul\u00e7in, \u0130. & Taslimi, P. Sulfonamide inhibitors: A patent review 2013\u2013present. Expert Opin. Ther. Pat. 28, 541\u2013549 (2018).","journal-title":"Expert Opin. Ther. Pat."},{"issue":"12","key":"41711_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13886","volume":"30","author":"Q Ning","year":"2023","unstructured":"Ning, Q. et al. CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. J. Viral Hepatitis. 30 (12), 951\u2013958 (2023).","journal-title":"J. Viral Hepatitis"},{"key":"41711_CR25","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.bmcl.2005.04.056","volume":"15","author":"V Garaj","year":"2005","unstructured":"Garaj, V. et al. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties. Bioorg. Med. Chem. Lett. 15, 3102\u20133108 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41711_CR26","doi-asserted-by":"publisher","first-page":"113837","DOI":"10.1016\/j.ejmech.2021.113837","volume":"226","author":"Y Wan","year":"2021","unstructured":"Wan, Y., Fang, G., Chen, H., Deng, X. & Tang, Z. Sulfonamide derivatives as potential anti-cancer agents and their SARs. Eur. J. Med. Chem. 226, 113837 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"41711_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.bioorg.2018.01.021","volume":"77","author":"HI Gul","year":"2018","unstructured":"Gul, H. I. et al. New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors. Bioorg. Chem. 77, 411\u2013419 (2018).","journal-title":"Bioorg. Chem."},{"key":"41711_CR28","doi-asserted-by":"publisher","first-page":"7761","DOI":"10.1016\/j.bmc.2006.08.002","volume":"14","author":"N Sirisoma","year":"2006","unstructured":"Sirisoma, N. et al. Discovery of substituted 4-anilino-2-(2-pyridyl)pyrimidines as apoptosis inducers. Bioorg. Med. Chem. 14, 7761\u20137773 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"41711_CR29","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bmcl.2009.02.074","volume":"19","author":"N Sirisoma","year":"2009","unstructured":"Sirisoma, N. et al. Discovery of substituted 4-anilino-2-arylpyrimidines as apoptosis inducers. Bioorg. Med. Chem. Lett. 19, 2305\u20132309 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41711_CR30","doi-asserted-by":"publisher","first-page":"217081","DOI":"10.1016\/j.ccr.2025.217081","volume":"546","author":"L Zhang","year":"2026","unstructured":"Zhang, L., Li, C. & Pang, S. Dual-aromaticity in nitrogen-rich compounds: from fundamental concepts to the application of high-energy-density materials. Coord. Chem. Rev. 546, 217081 (2026).","journal-title":"Coord. Chem. Rev."},{"key":"41711_CR31","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1021\/jm0501073","volume":"48","author":"A Cecchi","year":"2005","unstructured":"Cecchi, A. et al. Carbonic anhydrase inhibitors: Design of fluorescent sulfonamides. J. Med. Chem. 48, 4834\u20134841 (2005).","journal-title":"J. Med. Chem."},{"key":"41711_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07328303.2018.1543430","volume":"38","author":"GH Elgemeie","year":"2019","unstructured":"Elgemeie, G. H. & Mohamed, R. A. Microwave chemistry: Synthesis of purine and pyrimidine nucleosides. J. Carbohydr. Chem. 38, 1\u201347 (2019).","journal-title":"J. Carbohydr. Chem."},{"key":"41711_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1107\/S2056989021004126","volume":"77","author":"RA Mohamed-Ezzat","year":"2021","unstructured":"Mohamed-Ezzat, R. A., Elgemeie, G. H. & Jones, P. G. Crystal structures of pyrimidine derivatives. Acta Crystallogr. Sect. E. 77, 547\u2013550 (2021).","journal-title":"Acta Crystallogr. Sect. E"},{"key":"41711_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/00397911.2023.2175694","volume":"53","author":"EA Ahmed","year":"2023","unstructured":"Ahmed, E. A., Elgemeie, G. H. & Azzam, R. A. Synthesis of new sulfapyrimidine and pyrazolo derivatives. Synth. Commun. 53, 386\u2013401 (2023).","journal-title":"Synth. Commun."},{"key":"41711_CR35","doi-asserted-by":"publisher","first-page":"157677","DOI":"10.1016\/j.cej.2024.157677","volume":"501","author":"K Dou","year":"2024","unstructured":"Dou, K. et al. Switch on amine substrate reactivity towards hexaazaisowurtzitane cage: Insights from a tailored machine learning model. Chem. Eng. J. 501, 157677 (2024).","journal-title":"Chem. Eng. J."},{"key":"41711_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/1521-4184(200208)335:6<289::AID-ARDP289>3.0.CO;2-Z","volume":"335","author":"MN Nasr","year":"2002","unstructured":"Nasr, M. N. & Gineinah, M. M. Pyridopyrimidines as new antiviral agents. Arch. Pharm. 335, 289\u2013295 (2002).","journal-title":"Arch. Pharm."},{"key":"41711_CR37","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.bmcl.2009.02.067","volume":"19","author":"R Lin","year":"2009","unstructured":"Lin, R. et al. Synthesis and evaluation of thiazolopyrimidine analogues as EGFR inhibitors. Bioorg. Med. Chem. Lett. 19, 2333\u20132337 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41711_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1071\/CH00141","volume":"54","author":"SM Sondhi","year":"2001","unstructured":"Sondhi, S. M. et al. Anticancer and anti-inflammatory activity of heterocyclic compounds. Aust. J. Chem. 54, 69\u201374 (2001).","journal-title":"Aust. J. Chem."},{"key":"41711_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2174\/187152009788680028","volume":"9","author":"JY Winum","year":"2009","unstructured":"Winum, J. Y., Scozzafava, A., Montero, J. L. & Supuran, C. T. Inhibition of carbonic anhydrase IX. Anti-cancer Agents Med. Chem. 9, 693\u2013702 (2009).","journal-title":"Anti-cancer Agents Med. Chem."},{"key":"41711_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejmech.2017.04.037","volume":"14","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. Design and synthesis of BTK inhibitors. Eur. J. Med. Chem. 14, 60\u201369 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"41711_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/138527211794519041","volume":"15","author":"S Bondock","year":"2011","unstructured":"Bondock, S., Tarhoni, A. E. & Fadda, A. A. Recent progress in the synthesis and applications of heterocycles. Curr. Org. Chem. 15, 753\u2013781 (2011).","journal-title":"Curr. Org. Chem."},{"key":"41711_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.bioorg.2019.01.052","volume":"86","author":"N Ghareb","year":"2019","unstructured":"Ghareb, N., El-Sayed, N. M., Abdelhameed, R., Yamada, K. & Elgawish, M. S. Benzene-sulfonamide derivatives as PTP-1B inhibitors. Bioorg. Chem. 86, 322\u2013338 (2019).","journal-title":"Bioorg. Chem."},{"key":"41711_CR43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1142\/S1088424615500480","volume":"19","author":"AA Fadda","year":"2015","unstructured":"Fadda, A. A., El-Mekawy, R. E. & El-Shafei, A. I. Synthesis, antiviral and antitumor evaluations of porphyrins. J. Porphyr. Phthalocyanines. 19, 753\u2013768 (2015).","journal-title":"J. Porphyr. Phthalocyanines"},{"key":"41711_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.33263\/BRIAC133.239","volume":"13","author":"M Arshad","year":"2022","unstructured":"Arshad, M. & Matiychuk, V. Substituted pyrimidine-sulfonamide derivatives. Biointerface Res. Appl. Chem. 13, 239 (2022).","journal-title":"Biointerface Res. Appl. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41711-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:45:09Z","timestamp":1781642709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41711"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41711-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9820"}}